ACR适宜性标准®:乳腺癌新辅助全身治疗反应监测的影像学检查(2022年更新版)
该指南由美国放射学会(ACR)多学科专家小组制定,基于GRADE和RAND/UCLA适宜性方法系统分析同行评审文献,为乳腺癌新辅助化疗前、中、后影像学检查提供循证推荐。当同行评审文献缺乏或模棱两可时,专家意见可作为主要证据来源形成推荐。
要点
- 治疗决策高度依赖对新辅助化疗反应的准确影像学评估。
- 指南覆盖乳腺癌新辅助化疗前、中、后的影像学检查选择。
- 在文献缺乏或模棱两可时,专家意见可作为主要证据来源。
核心结论
- 影像学在管理接受新辅助化疗的患者中起重要作用,治疗决策高度依赖对治疗反应的准确评估。
- 本文件为乳腺癌新辅助化疗前、中、后影像学检查提供循证指南。
研究设计与样本
- 美国放射学会适宜性标准是由多学科专家小组每年审查的针对特定临床情况的循证指南。
- 指南制定与修订过程支持对同行评审期刊的医学文献进行系统分析。
- 采用GRADE等既定方法学原则评估证据,并使用RAND/UCLA适宜性方法用户手册确定特定临床场景下影像和治疗程序的适宜性。
- 在同行评审文献缺乏或模棱两可时,专家可能是可用于形成推荐的主要证据来源。
局限性
- 在同行评审文献缺乏或模棱两可的情况下,专家可能是可用于形成推荐的主要证据来源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Imaging plays a vital role in managing patients undergoing neoadjuvant chemotherapy, as treatment decisions rely heavily on accurate assessment of response to therapy. This document provides evidence-based guidelines for imaging breast cancer before, during, and after initiation of neoadjuvant chemotherapy. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
引用
- Hayward JH, Linden OE, Lewin AA, et al. ACR Appropriateness Criteria® Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer: 2022 Update. J Am Coll Radiol. 2023. PMID: 37236739. doi:10.1016/j.jacr.2023.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。